Lonza's Half-Year Surge: Margin Upgrade and Pure-Play Pivot
Strong H1 2026 performance with 16% CER sales growth and 4.4pp margin expansion drives upgraded guidance and signals a new era as a focused CDMO.
LONN.SW · Earnings Call · 2026-07-22
H1 2026: A Beat That Raises the Bar
Lonza delivered a standout first half, reporting sales of CHF 3.4 billion and a 16% CER sales growth, with CORE EBITDA margin expanding 4.4 percentage points to 34.8%. CEO Wolfgang Wienand opened the call with a clear message: “we are upgrading our full-year CORE EBITDA margin outlook to 33%-34% and reconfirm our expectation of 11%-12% CER sales growth.” — Wolfgang Wienand, CEO · 2026-07-22 This margin upgrade is not just a number—it reflects a fundamental shift in how the company is executing. The company's keyword trajectory for this quarter highlights CER sales growth as a top theme, alongside Advanced Synthesis and cash generation. These are not mere buzzwords; they are the pillars of the new Lonza. The margin expansion was broad-based, driven by operational execution, maturing growth projects, and favorable phasing. CFO Philippe emphasized that “this was a particularly strong first half, supported by a lower prior year base and favorable business phasing.” The underlying quality is visible in the ROIC improvement, which rose to 13.2%, nearly 3pp higher year-on-year. This is not just a revenue beat; it's a profit machine that is finally flexing.From Conglomerate to Pure-Play CDMO
The strategic narrative is also crystal clear. In less than 15 months, Lonza has divested four non-core assets, culminating in the agreement to sell Capsules & Health Ingredients (CHI). Wienand stated: “we have now completed our transformation into a pure-play CDMO at high pace.” — Wolfgang Wienand, CEO · 2026-07-22 This pivot is reflected in the rise of pure-play CDMO as a prominent keyword in the quarter. The company now focuses entirely on three business platforms, with the aim of delivering low-teens organic growth and expanding margins. The divestment also unlocks capital and simplifies the investment story, a point that has been a recurring theme in prior calls. In the January 2026 call, management had already hinted at the benefits of the transformation, with Philippe noting that the exit of CHI would likely boost ROIC. Now that it's contracted, investors can see a clearer path.Platforms: All Three Engines Firing
The H1 results show every platform contributing to the growth. Exceptional growth in Advanced Synthesis (27.7% CER) and a return to growth in Specialized Modalities (22.6% CER) were the standouts. The operational execution across the network is improving, and the company is investing to sustain momentum. Two new ADC-related projects in Visp and Stein were announced, expanding payload-linker capacity and fill-finish capabilities. Wienand noted: “We continue to see strong customer demand in this area, supporting our confidence in the long-term opportunity.” This is consistent with the global shift toward biologics and ADCs, and Lonza is positioning itself as the go-to partner. In the Q&A, management was pressed on whether the H1 phasing would distort the full-year picture. CFO Philippe explained that the outsized ADS margins (48.1% in H1) would normalize in H2, but he remained comfortable with the upgraded guidance. The discussion also touched on the Cell & Gene business, which had faced operational challenges in 2025. On the current call, Philippe confirmed that “production has resumed, and this will contribute to the second half performance of cell and gene.” This aligns with the prior call in January 2026, where management had expressed confidence that CGT would grow in 2026 after resolving last year's issues (“we're confident in terms of the growth rate for Cell & Gene in '26 versus '25” — Philippe Deecke, CFO or Finance Executive · 2026-01-28). The new CGT momentum is a key swing factor.Visibility and the H2 Normalization
Investors were worried about the implied H2 growth slowdown, but management pushed back with a focus on the full year. Wienand argued that the lumpiness is inherent in the business: “Lonza is not a cookies factory.” The company's ability to hold guidance despite the heavy H2 base reflects its confidence. Favorable phasing is a recurring theme in this quarter's keywords, and it's a tool management uses to explain the rhythm without admitting to weakness. The H2 story is supported by the ramp-up of the Visp large-scale mammalian asset and the expected contributions from Cell & Gene. The fact that the company sees further margin expansion even as ADS normalizes suggests a diversified strength.Cash Generation and the Next Phase
Free cash flow nearly quadrupled to CHF 426 million, a direct result of higher earnings and disciplined capex. The CapEx-to-sales ratio fell from 21.2% to 15.7%, a sign that the heavy investment phase is maturing. This ties back to the discretionary cash that management has promised to allocate wisely. With at least CHF 7 billion in planned organic capex through 2030, Lonza is betting on its own capabilities to drive mid-teens returns. The pure-play structure gives investors a direct line to the CDMO economics, and the upgraded margin guide is the clearest signal yet that the Lonza Engine is working.In summary, Lonza's H1 2026 is a confirmation of its strategic direction and an execution beat. The upgraded margin outlook, the pure-play pivot, and the broad-based growth across platforms make this a name in motion. The key risk is the H2 normalization, but management's tone and the forward-looking indicators suggest they have it under control. This is a company that has transformed itself and is now reaping the rewards.The sustained trend towards outsourcing across the biopharma industry is reflected in the modest end, based on our historic and forward-looking analysis, unchanged CapEx to sales ratios of the largest pharmaceutical companies.